• Aucun résultat trouvé

Scope of centres of expertise for rare diseases in European countries where they exist

N/A
N/A
Protected

Academic year: 2021

Partager "Scope of centres of expertise for rare diseases in European countries where they exist"

Copied!
2
0
0

Texte intégral

(1)

HAL Id: inserm-00756025

https://www.hal.inserm.fr/inserm-00756025

Submitted on 22 Nov 2012

HAL is a multi-disciplinary open access

archive for the deposit and dissemination of

sci-entific research documents, whether they are

pub-lished or not. The documents may come from

teaching and research institutions in France or

abroad, or from public or private research centers.

L’archive ouverte pluridisciplinaire HAL, est

destinée au dépôt et à la diffusion de documents

scientifiques de niveau recherche, publiés ou non,

émanant des établissements d’enseignement et de

recherche français ou étrangers, des laboratoires

publics ou privés.

Scope of centres of expertise for rare diseases in

European countries where they exist

Charlotte Rodwell, Ségolène Aymé, Kate Bushby

To cite this version:

Charlotte Rodwell, Ségolène Aymé, Kate Bushby. Scope of centres of expertise for rare diseases

in European countries where they exist. 6th European Conference on Rare Diseases and Orphan

Products, May 2012, France. pp.A5. �inserm-00756025�

(2)

M E E T I N G A B S T R A C T

Open Access

Scope of centres of expertise for rare diseases

in European countries where they exist

Charlotte Rodwell

1*

, Ségolène Aymé

1

, Kate Bushby

2

From 6th European Conference on Rare Diseases and Orphan Products

Brussels, Belgium. 23-25 May 2012

The development of centres of expertise (CE) and European Reference Networks (ERN) in the field of rare diseases (RD) is encouraged in the Council Recommen-dation on an Action in the Field of RD (2009/C 151/02) (8 June 2009) and most recently in the Directive on the application of patients’ rights in cross-border healthcare (2011/24/EU) (9 March 2011) as a means of organising care for thousands of heterogeneous RD affecting scat-tered patient populations across Europe. The European Union Committee of Experts on Rare Diseases (EUCERD http://www.eucerd.eu) issued a set of Recommendations on Quality Criteria for Centres of Expertise for Rare Dis-eases in Member States[1] to guide Member States (MS) in this area.

The scope of CE in terms of disease coverage is an important issue as the expectation is to provide CE for all RD patients’ needs at national level. Denmark, France, Norway, Spain and the UK, for example, have already identified existing expertise at national level and/or established centres specialised in some RD/groups of RD which have proven to be very efficient in improving qual-ity of care. The Scientific Secretariat of the EUCERD examined the current scope of CE in countries where they exist. CE were grouped by medical area. Three or more MS have designated centres for: juvenile arthritis/ paediatric rheumatological diseases, developmental anomalies and malformations/dysmorphology, hereditary cardiac diseases, dermatological diseases, epidermolysis bullosa, pituitary diseases or hypothalamic-hypophyseal diseases, lysosomal diseases, Prader-Willi syndrome, Fabry disease, mitochondrial diseases, haemophilia/con-stitutional bleeding disorders, mastocytosis, hereditary diseases of the metabolism, porphyrias, epilepsies,

neuromuscular diseases, amyotrophic lateral sclerosis, pulmonary diseases, severe pulmonary hypertension, cys-tic fibrosis, hereditary immune deficiencies, opthalmolo-gical diseases, genetic kidney disease, cranofacial anomalies, neurofibromatosis, Rendu-Osler disease.

On the basis of this experience, a consensus can be thus identified that centres are required for around 12 groups of RD, 30 subgroups, and 26 individual diseases where centres currently exist in two or more countries. Most of these groups of RD fit into the traditional organisation of health-care by medical area. However some grouping outside of traditional medical specialities is necessary, e.g. diseases of connective tissue, rare bone diseases, neurofibromatosis, multimalformation syndromes with intellectual disability, mitochondrial diseases, lysosomal diseases, any multi-systemic complex disease, etc. This analysis could be of use for MS currently considering the organisation of CE for RD. This work was carried out by the EUCERD Scientific Secretariat with the support of EC Joint Action N° 20082291.

Author details

1European Union Committee of Experts on Rare Diseases (EUCERD) Scientific

Secretariat, INSERM US 14, Paris, France.2Network of Excellence TREAT-NMD,

Institute of Human Genetics, Newcastle University, Newcastle, UK. Published: 22 November 2012

Reference

1. European Union Committee of Experts on Rare Diseases:

Recommendations on Quality Criteria for Centres of Expertise for Rare Diseases in Member States. [http://www.eucerd.eu/upload/file/ EUCERDRecommendationCE.pdf].

doi:10.1186/1750-1172-7-S2-A5

Cite this article as: Rodwell et al.: Scope of centres of expertise for rare diseases in European countries where they exist. Orphanet Journal of Rare Diseases 2012 7(Suppl 2):A5.

* Correspondence: charlotte.rodwell@inserm.fr

1

European Union Committee of Experts on Rare Diseases (EUCERD) Scientific Secretariat, INSERM US 14, Paris, France

Full list of author information is available at the end of the article Rodwell et al. Orphanet Journal of Rare Diseases 2012, 7(Suppl 2):A5 http://www.ojrd.com/content/7/S2/A5

© 2012 Rodwell et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Références

Documents relatifs

L’archive ouverte pluridisciplinaire HAL, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des

Academic research continues to document that corporate insiders earn abnormal profits on trade in corporate stock, and at the same time, capital market regulators

An example of another very interesting class of irrelevant dependencies is shown in Figure 9, where the dependency for package a can always be satisfied despite the conflict

Pour ce, on peut formuler l’hypothèse que plus les directions sont capables de gérer sainement leurs émotions, plus elles sont aussi en mesure de prendre conscience des

Case not detected Farmer detects symptoms and calls a veterinarian No Yes Case not detected Veterinarian has a bTB suspicion and conducts a tuberculin test No Yes CASE

L’archive ouverte pluridisciplinaire HAL, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des

In the past 20 years, there have been significant advances in the knowledge and management of rare pulmonary diseases. This has been made possible by several factors, including: 1)

4 Département d’Etudes Cognitives, École normale supérieure, PSL University, Paris, France, 5 Inserm U955, Institut Mondor de Recherche Biomédicale, Equipe E01